Updated:
Xora Innovation
Xora Innovation is Temasek's early-stage deep tech arm, leading Seed and Series A rounds from Singapore into hard-science startups across the US and Asia.
Xora Innovation
Xora Innovation launched in 2019 as a wholly owned subsidiary of Temasek Holdings, designed to capture early-stage breakthroughs in science and technology. Donna See led the firm as founding CEO through 2023, establishing the investment posture before transitioning board roles across portfolio companies; Alan Thompson now serves as CEO alongside Managing Partner and CIO Phil Inagaki, who oversees investment strategy from Singapore. The parentage matters: Temasek's permanent-capital structure removes the fundraising clock that shapes most venture partnerships. Xora leads or co-leads Seed and Series A rounds, concentrating on hard-science ventures where the path to product requires lab validation, regulatory clearance, or novel manufacturing. The firm has pursued deals across quantum computing, advanced materials, synthetic biology, and fusion energy — asset classes where thesis conviction and multi-year hold periods dominate. In 2023, Xora co-anchored a S$75 million deep-tech commercialization pilot with the National University of Singapore and Nanyang Technological University (per Altss research), flagging a deliberate pipeline strategy: convert university-originated IP into fundable companies at the pre-Series A stage. Direct investments often place Xora alongside US-based specialist funds, with deal teams operating out of both Singapore and a San Francisco office at 101 Mission Street. Team size is not publicly disclosed. The San Francisco presence provides proximity to Bay Area founder networks and co-investor syndicates, while the Singapore headquarters maintains direct access to Temasek's balance sheet and Asia-Pacific institutional relationships. The firm holds full membership in the Singapore Venture & Private Capital Association (SVCA), reinforcing a dual-regulator posture across Singapore and US deal jurisdictions. Xora's structure sidesteps a constraint common to independent deep-tech funds: limited partner redemption pressure. Because Temasek supplies the capital without a fixed fund life, Xora can hold positions through scientific inflection points that outlast a standard 10-year fund. This architecture resembles other sovereign-backed venture platforms — Mubadala Ventures, for instance — but Xora's narrower aperture on Seed and Series A hard-tech differentiates it from the growth-stage mandate typical of state-linked investors. Succession from founding CEO to an external operating executive, while Inagaki retains investment authority, signals a maturation from launch-phase entrepreneurship to institutional repeatability.
General information
Firm type
Generalist
Year founded
2019
AUM
Undisclosed
Location
Region
Asia
Country
Singapore
City
Singapore
Corporate office
1 Fusionopolis Way, Singapore
Additional offices
San Francisco, CA, United States
Principals
Phil Inagaki
Managing Partner / CIO
Alan Thompson
CEO
Donna See
Founding CEO (2019-2023)
Sector focus
Frequently asked questions
Who runs investment decisions at Xora Innovation?
Phil Inagaki is Managing Partner and Chief Investment Officer, overseeing investment strategy and portfolio management. Alan Thompson serves as CEO, handling firm operations. Founding CEO Donna See ran Xora from 2019 through 2023 and remains on portfolio company boards. Investment authority sits with Inagaki's team, not a distant Temasek committee.
Is Xora structured as a family office or a venture firm?
Xora is an early-stage investment platform wholly owned by Temasek Holdings, Singapore's sovereign wealth fund. The legal structure is a subsidiary corporation, not a traditional GP/LP venture fund. This gives Xora permanent capital without external limited partners, and compensation likely differs from standard venture carry models — though specifics are not disclosed.
What stages and check sizes does Xora target?
Xora leads or co-leads Seed and Series A rounds in the science and technology ecosystem. No published check-size range is available, but the Seed-to-Series-A focus and Temasek balance sheet suggest capacity for first-institutional rounds up to typical Series A sizes in deep tech — often $5M to $20M depending on sector and syndicate structure.
How is Xora related to Temasek, and does it invest Temasek's broader capital?
Xora is a wholly owned subsidiary of Temasek Holdings, created specifically as an early-stage investment platform. It is not Temasek's sole venture activity — Temasek also invests in growth-stage and later-stage companies directly and through other vehicles. Xora's mandate is confined to early-stage deep tech, operating with decision-making autonomy under its own investment team.
How does Xora source proprietary deal flow?
The firm operates a S$75 million deep-tech commercialization pilot in partnership with the National University of Singapore and Nanyang Technological University, designed to spin out ventures from university research labs. Additionally, the San Francisco office on Mission Street places deal teams in proximity to Bay Area founders, accelerator graduates, and specialist deep-tech syndicates. Temasek's institutional relationships in Asia provide a secondary sourcing channel.
Which sectors does Xora explicitly avoid?
No public exclusion list exists. However, Xora's stated focus on science and technology ecosystems and its portfolio pattern suggest the firm avoids consumer internet, enterprise SaaS without hard-tech IP, and business models built solely on marketplace or advertising economics. The emphasis is on ventures requiring defensible scientific moats — quantum, advanced materials, synthetic biology, and industrial automation.
What is Xora's posture on co-investing alongside external venture funds?
Xora co-leads rounds alongside other venture funds, indicating willingness to syndicate rather than dominate cap tables. The firm's permanent-capital structure makes it an attractive co-investor for fund managers who want a patient, non-FOMO partner on multi-year R&D timelines. Specific co-investment partners are not systematically disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: